Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
April 29 2021 - 10:41AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred
to as “Dr. Reddy’s”) today announced the launch of Albendazole
Tablets, USP, a therapeutic equivalent generic version of Albenza
Tablets, 200 mg, approved by the U.S. Food and Drug Administration
(USFDA).
The Albenza brand and generic had U.S. sales of approximately
$27 million MAT for the most recent twelve months ending in
November 2020 according to IQVIA Health*.
Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg
tablets in bottle count sizes of two.
Albenza is a trademark of Glaxosmithkline
Please see the full prescribing information.
https://www.drreddys.com/pil/Albendazole-200mg-Outsert-v_2.pdf
*IQVIA National Sales Perspective: Retail and Non-Retail MAT
November 2020
RDY-0221-331
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated
pharmaceutical company, committed to providing affordable and
innovative medicines for healthier lives. Through its three
businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products – Dr. Reddy’s offers a
portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy’s operates in markets across
the globe. Our major markets include – USA, India, Russia & CIS
countries, and Europe. For more information, log on to:
www.drreddys.com.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may," "will,"
"should," "expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, (vi) the susceptibility of
our industry and the markets addressed by our, and our customers’,
products and services to economic downturns as a result of natural
disasters, epidemics, pandemics or other widespread illness,
including coronavirus (or COVID-19), and (vii) other risks and
uncertainties identified in our public filings with the Securities
and Exchange Commission, including those listed under the "Risk
Factors" and "Forward-Looking Statements" sections of our Annual
Report on Form 20-F for the year ended March 31, 2020. The company
assumes no obligation to update any information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005769/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph:
+91-40-49002135)
MEDIA RELATIONS PRANAV PRIMLANI
pranav.primlani@drreddys.com (PH: +91-9381905796)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024